VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody

References

• AllumWHPowellDJMcConkeyCCFieldingJWGastric cancer: a 25-year reviewBr J Surg19897665355402758258
   PubMed Web of Science ®Google Scholar
• MaruyamaKKaminishiMHayashiKGastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Japanese Gastric Cancer Association Registration CommitteeGastric Cancer200692516616767357
   PubMedGoogle Scholar
• Van CutsemEMoiseyenkoVMTjulandinSV325 Study GroupPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• KoizumiWNaraharaHHataTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialLancet Oncol20089321522118282805
   PubMed Web of Science ®Google Scholar
• SatoYTakayamaTSagawaTPhase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancerCancer Chemother Pharmacol201066472172820041328
   PubMed Web of Science ®Google Scholar
• ChuDZLangNPThompsonCOsteenPKWestbrookKCPeritoneal carcinomatosis in nongynecologic malignancies. A prospective study of prognostic factorsCancer19896323643672910444
   PubMed Web of Science ®Google Scholar
• SadeghiBArvieuxCGlehenOPeritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective studyCancer200088235836310640968
   PubMed Web of Science ®Google Scholar
• YonemuraYEndouYYamaguchiTMechanisms of the formation of the peritoneal dissemination in gastric cancerInt J Oncol19968479580221544429
   PubMed Web of Science ®Google Scholar
• ConnollyDTHeuvelmanDMNelsonRTumor vascular permeability factor stimulates endothelial cell growth and angiogenesisJ Clin Invest1989845147014782478587
   PubMed Web of Science ®Google Scholar
• LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience19892464935130613092479986
   PubMed Web of Science ®Google Scholar
• MesianoSFerraraNJaffeRBRole of vascular endothelial growth factor in ovarian cancer. Inhibition of ascites formation by immunoneutralizationAm J Pathol19981534124912569777956
   PubMed Web of Science ®Google Scholar
• ByrneATRossLHolashJVascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer modelClin Cancer Res20039155721572814654557
   PubMed Web of Science ®Google Scholar
• ShererDMEliakimRAbulafiaOThe role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the femaleGynecol Obstet Invest200050421722411093042
   PubMed Web of Science ®Google Scholar
• AoyagiKKouhujiKYanoSVEGF significance in peritoneal recurrence from gastric cancerGastric Cancer20058315516316086118
   PubMedGoogle Scholar
• LiLWangLZhangWCorrelation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancerAnticancer Res2004243b1973198015274387
   PubMed Web of Science ®Google Scholar
• KayaACiledagAGulbayBEThe prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patientsRespir Med200498763263615250229
   PubMed Web of Science ®Google Scholar
• AlabiAASuppiahAMaddenLAMonsonJRGreenmanJPreoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patientsDis Colon Rectum200952599399919502868
   PubMed Web of Science ®Google Scholar
• VidalOMetgesJPElizaldeIHigh preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancerBr J Surg200996121443145119918848
   PubMed Web of Science ®Google Scholar
• Japanese Research Society for Gastric CancerJapanese Classification of Gastric Carcinoma1st EnglishTokyo, JapanKanehara1995
   Google Scholar
• KinoshitaJFushidaSMakinoI[The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites – two case reports.]Gan To Kagaku Ryoho2011381223602362 Japanese22202382
   PubMedGoogle Scholar
• KamiyamaMIchikawaYIshikawaTVEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude miceCancer Gene Ther20029219720111857038
   PubMed Web of Science ®Google Scholar
• BabaMKonnoHMaruoYRelationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancerEur Surg Res19983021301379565747
   PubMed Web of Science ®Google Scholar
• ImaizumiTAoyagiKMiyagiMShirouzuKSuppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis modelSurg Today201040985185720740349
   PubMed Web of Science ®Google Scholar
• SakoAKitayamaJYamaguchiHVascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasisJ Surg Res2003115111312014572781
   PubMed Web of Science ®Google Scholar
• PertovaaraLKaipainenAMustonenTVascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cellJ Biol Chem19942699627162748119973
   PubMed Web of Science ®Google Scholar
• HermeyJHDimitriadisEKayERdmondHPBouchier-HayesDRegulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1Ann Surg Oncol1998532712789607631
   PubMed Web of Science ®Google Scholar
• RudlowskiCPickartAKFuhljahnCPrognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-upInt J Gynecol Cancer200616Suppl 1S183S189
   PubMed Web of Science ®Google Scholar
• MaedaKChungYSOgawaYPrognostic value of vascular endothelial growth factor expression in gastric carcinomaCancer19967758588638608475
   PubMed Web of Science ®Google Scholar
• SaitoHTsujitaniSKondoAIkeguchiMMaetaMKaibaraNExpression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinomaSurgery1999125219520110026754
   PubMed Web of Science ®Google Scholar
• IchikuraTTomimatsuSOhkuraEMochizukiHPrognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinomaJ Surg Oncol200178213213711579392
   PubMed Web of Science ®Google Scholar
• KarayiannakisAJSyrigosKNPolychrondisACirculating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgeryAnn Surg20022361374212131083
   PubMed Web of Science ®Google Scholar
• YoshikawaTTsuburayaAKobayashiOSairenjiMMotohashiHYanomaSPlasma concentration of VEGF and b-FGF in patients with gastric carcinomaCancer Lett20001531–271210779624
   PubMed Web of Science ®Google Scholar
• ShahMARamanathanRKIlsonDHMulticenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophaeal junction adenocarcinomaJ Clin Oncol200624335201520617114652
   PubMed Web of Science ®Google Scholar
• OhtsuAShahMAVan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized double-blind, placebo-controlled phase III studyJ Clin Oncol201129303968397621844504
   PubMed Web of Science ®Google Scholar
• Della PortaMDanovaMRigolinGMDendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicopathological findingsOncology2005682–327628416015045
   PubMed Web of Science ®Google Scholar
• LiBLalaniASHardingTCVascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapyClin Cancer Res200612226808681617121902
   PubMed Web of Science ®Google Scholar
• BamiasAKoutsoukouVTerposECorrelation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFa in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapyGynecol Oncol2008108242142718036640
   PubMed Web of Science ®Google Scholar
• ZhangXSZhuXFGaoJSMultiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165Acta Pharmacol Sin200122873173511749847
   PubMed Web of Science ®Google Scholar
• NinomiyaSInomataMTajimaMEffect of bevacizumab monoclonal antibody to vascular endothelial growth factor, on peritoneal matastasis of MKN-45P human gastric cancer in miceJ Surg Res2009154219620219329124
   PubMed Web of Science ®Google Scholar
• NumnumTMRocconiRPWhitworthJBarnesMNThe use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinomaGynecol Oncol2006102342542816797681
   PubMed Web of Science ®Google Scholar
• HamiltonCAMaxwellGLChernofskyMRBernsteinSAFarleyJHRoseSIntraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancerGynecol Oncol2008111353053218561992
   PubMed Web of Science ®Google Scholar
• YagiYFushidaSHaradaSBiodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in miceCancer Chemother Pharmacol201066474575320033809
   PubMed Web of Science ®Google Scholar